

FDA-AACR Real-world Evidence Workshop

July 19, 2019 Bethesda Doubletree by Hilton | Bethesda, MD

Workshop Cochairs:

U.S. Food and Drug Administration:

Sean Khozin, MD, MPH, Associate Director, Oncology Center of Excellence, Director, Information Exchange and Data Transformation (INFORMED), U.S. Food and Drug Administration
Pallavi Mishra-Kalyani, PhD, Team Leader, Division of Biometrics V, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

American Association for Cancer Research:

Deborah Schrag, MD, MPH, Chief, Division of Population Sciences, Dana-Farber Cancer Institute

	AGENDA	
INTRODUCTION		
8:00 AM	Introduction & Objectives	
	Workshop cochair	
	SESSION I: INTRO TO REAL-WORLD EVIDENCE	
This session will introduce real-world evidence concepts and the utility of using real-world data sources.		
8:05 AM	Keynote: FDA Framework on Real-world Evidence	
	Jacqueline Corrigan-Curay, JD, MD, U.S. Food and Drug Administration	
8:45 AM	Intro to RWE - utility, clinical decision support	
	Elad Sharon, MD, MPH, National Cancer Institute	
	SESSION II: PREMARKET USE CASES	
SESSION MODERATOR: PALLAVI MISHRA-KALYANI, PHD		
This session will provide examples of using real-world evidence in drug development.		
9:05 AM	Michael Kelsh, PhD, MPH, Amgen	
9:25 AM	William Capra, PhD, Genentech	
9:45 AM	Weili He, PhD, AbbVie	
10:05 AM	PANEL DISCUSSION and AUDIENCE Q&A	
Panelists:	Session II speakers and the following additional panelists:	
	Rajeshwari Sridhara, PhD, U.S. Food and Drug Administration	
10:35 AM	BREAK	
@FDAOncology		@AACR

Join the conversation with #OCEAACRRWE

SESSION III: POSTMARKET USE CASES SESSION MODERATOR: PALLAVI MISHRA-KALYANI, PHD

This session will provide examples of using real-world evidence in postmarket situations.

10:55 AM	Albert L. Kraus, PhD, Pfizer
11:15 AM	Ruthanna Davi, PhD, Medidata Solutions
11:35 AM	Jeff Allen, PhD, Friends of Cancer Research
11:55 AM	PANEL DISCUSSION and AUDIENCE Q&A
Panelists:	Session III speakers and the following additional panelists:
	Mark Levenson, PhD, U.S. Food and Drug Administration
	Frank W. Rockhold, PhD, Duke Clinical Research Institute
12:20 PM	LUNCH (ON YOUR OWN)

SESSION IV: LARGE GENOMIC DATABASES & REAL-WORLD EVIDENCE SESSION MODERATOR: DEBORAH SCHRAG, MD, MPH

This session will explore large genomic databases and digital data as real-world sources of information.

1:20 PM	ASCO CancerLinQ Wendy Rubinstein, MD, PhD, CancerLinQ
1:32 PM	The NCI Genomic Data Commons and Cancer Research Data Commons and Real-world Data Robert Grossman, PhD, University of Chicago
1:44 PM	ORIEN William S. Dalton, PhD, MD, M2Gen
1:56 PM	Flatiron Health Neal Meropol, MD, Flatiron Health
2:08 PM	Tempus Gary Palmer, MD, Tempus
2:20 PM	Syapse Jonathan Hirsch, Syapse
2:32 PM	AACR GENIE Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute
2:44 PM	PANEL DISCUSSION and AUDIENCE Q&A
Panelists:	Session IV speakers
3:05 PM	BREAK

SESSION V: REAL-WORLD EVIDENCE - FUTURE DIRECTIONS SESSION MODERATOR: ERIC PERAKSLIS, PHD

This session will explore the future of real-world evidence.

3:20 PM	Digital Health Technology
	Andrea Coravos, Elektra Labs
3:35 PM	Digital Phenotyping
	James Gulley, MD, PhD, National Cancer Institute
3:50 PM	Perpetual Trials
	Mark Shapiro, MBA, PhD, xCures
4:05 PM	PANEL DISCUSSION and AUDIENCE Q&A
Panelists:	Session V speakers and the following additional panelists:
	Pallavi Mishra-Kalyani, PhD, U.S. Food and Drug Administration
	Deborah Schrag, MD, MPH, Dana-Farber Cancer Institute
	Oliver Bogler, PhD, ECHO Institute
	Rohit Borker, PhD, Novartis
4:55 PM	Wrap up: Summary
	Workshop cochair
5:00 PM	ADJOURN

